| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99205 |
Prolong outpt/office vis |
8,737 |
8,692 |
$650K |
| 99215 |
Prolong outpt/office vis |
7,211 |
6,427 |
$399K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
5,539 |
5,387 |
$283K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,984 |
3,964 |
$192K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,380 |
7,796 |
$192K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,475 |
3,231 |
$103K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,115 |
1,111 |
$38K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,073 |
1,843 |
$38K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,029 |
3,905 |
$25K |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
2,979 |
2,809 |
$9K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,165 |
1,650 |
$8K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,386 |
3,044 |
$7K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
261 |
250 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
299 |
284 |
$3K |
| 99072 |
|
1,156 |
1,069 |
$3K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
169 |
161 |
$3K |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
169 |
161 |
$2K |
| 99401 |
|
1,469 |
1,385 |
$2K |
| 81003 |
|
2,139 |
2,091 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
441 |
432 |
$1K |
| 86328 |
|
113 |
109 |
$1K |
| 86769 |
|
113 |
109 |
$968.99 |
| 99051 |
|
255 |
248 |
$550.71 |
| 96127 |
|
202 |
194 |
$401.87 |
| 99070 |
|
104 |
103 |
$278.01 |
| 99000 |
|
540 |
535 |
$242.34 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
299 |
296 |
$237.09 |
| G2024 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source |
49 |
48 |
$203.68 |
| 86635 |
|
58 |
55 |
$142.20 |
| A9150 |
Non-prescription drugs |
55 |
55 |
$81.16 |
| J3490 |
Unclassified drugs |
275 |
266 |
$70.19 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
85 |
83 |
$46.36 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
94 |
90 |
$41.50 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
98 |
94 |
$40.97 |
| 81002 |
|
214 |
212 |
$36.35 |
| 82948 |
|
81 |
81 |
$31.65 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
128 |
125 |
$7.19 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
224 |
223 |
$4.77 |
| 81000 |
|
62 |
61 |
$0.00 |
| 85018 |
|
30 |
30 |
$0.00 |
| 99173 |
|
39 |
39 |
$0.00 |
| A4550 |
Surgical trays |
15 |
12 |
$0.00 |
| 81025 |
|
17 |
16 |
$0.00 |